Roche’s Obesity Pill Candidate Hit With Safety Concerns Despite Strong Efficacy Data

When doses werer increased rapidly in a Phase I study, patients on Roche’s investigational oral GLP-1 receptor agonist experienced nausea, vomiting, constipation, diarrhea, as well as abdominal and distention.